Our Team

As an innovator for over 25 years, Allan Camaisa is an extraordinarily successful entrepreneur, investor, and technologist who brings state-of-the-art software application and system solutions and services to healthcare organizations, government agencies, and commercial enterprises. He has been a founder of several successful enterprises and brought measurable C-level executive leadership to start-up companies struggling to achieve operational success which required extensive turnaround and repositioning strategies.

Mr. Camaisa is the current Chief Executive Officer (CEO) of Calidi Biotherapeutics and oversees execution of the Calidi Biotherapeutics business and financial operations. Calidi Biotherapeutics mission is to eradicate difficult to treat cancers. Calidi Biotherapeutics patented technology enables patients to undergo treatment with none of the well-known debilitating side effects associated with traditional cancer treatments such as hair loss, appetite loss, weight loss, nausea, harm to healthy living tissue and other detrimental health concerns. The Calidi Biotherapeutics approach leverages a patient’s own cells, bundled with a proprietary anti-cancer payload which is then targeted directly at tumorous cells while sparing the patient’s healthy cells to allow the patient’s immune system to fight and ultimately kill the cancer cells.

Previously Mr. Camaisa was the CEO and Chairman of Parallel6, Inc., whose digital mobile software platform engaged clinical trial participants, and powered the enrollment, engagement, management, and retention of those participants on behalf of pharmaceutical organizations. Parallel6 was sold to PRA Health Sciences (NASDAQ:PRAH) in Q2 of 2017. Mr. Camaisa was also instrumental in providing the company’s Series A funding. Some of their clients included, Sanofi, STSI/Genentech, Thermal Fisher, Johnson & Johnson/Janssen, Abbott/Abbvie, PPD, PRA Health, Pfizer, Roche, and the NIH, among others.

Mr. Camaisa previously founded AnakamTM, Inc., a software security company, also focused on healthcare, which safeguarded medical records online through a platform delivering NIST Level 3 multifactor authentication and security. Anakam sold over 5 million licenses to the Veterans Administration (VA) for deployment across 250 global locations, to the Center for Medicare and Medicaid, to the Department of Homeland Security and to medical device companies such as Boston Scientific and EntraHealth. Anakam was recognized by INC 500 as one of the fastest growing companies in the U.S. Equifax, Inc (NYSE:EFX) subsequently acquired Anakam in 2010.

Preceding Anakam™, Mr. Camaisa’s High Technology Solutions TM (HTS), a software systems integrator with over $50 million in revenues which was recognized as an INC 500 company three years in a row. Mr. Camaisa led HTS from a small, two-person company to one with 500+ employees across the US. HTS was sold to Wireless Facilities, Inc., now Kratos Defense (NASDAQ:KTOS) in 2004.

Mr. Camaisa successfully raised $17 million funding in 1999 from GE Capital, Intel, Ford Motor Company, and JP Morgan Chase Hambrecht & Quist to launch an Internet company, Eye Velocity, that focused on Internet Visualization.

Mr. Camaisa owns 7 U.S. patents and has received various awards from Tech America, the U.S. Small Business Association, the Asian Business Association and Deloitte FAST 50. He has been recognized and honored with the Governor's Small Business of the Year Award, the 1998 Ernst and Young Regional Entrepreneur of the Year in the Internet and Software Category and as the SBA Small Business Person of the Year.

He is a graduate of both the United States Naval Academy and the prestigious Owners Management Program at Harvard Business School.

Mr. Camaisa enthusiastically serves as member of YPO (Young Presidents Organization) San Diego Coastal Chapter as he has on several other volunteer boards including the United Way of San Diego and Opportunity International (Micro-Enterprise Loans to the Poor).

Dr. Minev is a highly accomplished physician-scientist with extensive industrial and academic experience in Immuno-Oncology, oncolytic viruses and stem cell biology and applications. He has a significant track record in tumor immunology and cancer vaccine development, having worked closely on the development of the first cancer vaccine to be approved by a regulatory body (Melacine).

Dr. Minev has also extensive expertise in immunotherapy clinical trial designs, logistics, and regulatory issues. He has a considerable supervision & management experience in industrial and academic settings and excellent skills in biotech business development, communication, and collaboration.

Prior to joining Calidi Biotherapeutics, Dr. Minev was the Director of Immunotherapy and Translational Oncology at Genelux Corporation, where he was directing several preclinical and translational projects on oncolytic virotherapy, immunotherapy, and nanotechnology.

Dr. Minev is also an Adjunct Professor at the Moores UCSD Cancer Center. There, he served previously as Principal Investigator and Director, Laboratory of Tumor Immunology and Immunotherapy where, for more than 15 years, his research has been focused on the discovery of new target antigens for immunotherapy of cancer and the development of optimized cancer vaccines. Prior to that, Dr. Minev worked in Dr. Steven Rosenberg's Tumor Immunology Section at the Surgery Branch of the National Cancer Institute.

Dr. Minev is an Advisory Board Member of the European Society for Translational Medicine (EUSTM). He is a member of the Scientific and Clinical Advisory Boards of several biotechnology companies and has been an advisor for Amgen, Johnson & Johnson, Geron Corporation, McKinsey Consulting and Thomson Current Drugs, among others. He is the recipient of the European Association of Cancer Research Fellowship and the Fogarty International Fellowship.

Mr. Keane is a seasoned life sciences executive with an extensive track record of success in corporate development, business development and financial transactions for emerging biopharmaceutical companies. He has been an officer of four publicly traded companies, raised over $400 million in equity capital in the last two decades and has helped generate more than $400 million in non-dilutive partner revenues to fund drug discovery programs. Mr. Keane is currently CBO of Stemimmune. He is co-founder of Staurus Pharma, served as SVP of Corporate Development of Leading Biosciences, President and CEO of Femta Pharmaceuticals and has held senior corporate development positions with Cosmo Pharmaceuticals S. A., Ambit Biosciences, Dendreon Corp., Corvas International, Epimmune Inc., SIBIA Neurosciences and Molecular Biosystems. He was responsible for negotiating significant alliances including licenses, distributions agreements, technology acquisitions and research agreements with large pharmaceutical companies and government agencies. He also served as the principal negotiator for Dendreon’s acquisition of Corvas International and Merck’s acquisition of SIBIA Neurosciences. He holds a Bachelor of Arts in English Literature from San Diego State University.